123 FRAIL-AF RANDOMISED CONTROLLED TRIAL: RESULTS FUNDING The FRAIL-AF study was mainly supported by The Netherlands Organisation for Health Research and Development (ZonMw number 848015004). The University Medical Center Utrecht supported this study with additional institutional funding. Furthermore, the FRAIL-AF study received unrestricted educational grants of all four NOAC selling pharmaceutical companies (Boehringer-Ingelheim, Bayer Healthcare, BMS Pfizer, Daiichi Sankyo) for symposia and for the development of training material. There were no restrictions to the execution of the study or the publication process by any of the subsiding parties as confirmed by the Dutch Advertising Code Committee. GJG is supported by a VENI and VIDI grant from the Netherlands Organisation for Health Research and Development (ZonMw numbers 016.166.030 and 016.196.304). POTENTIAL CONFLICTS OF INTEREST SvD reports an unrestricted research grant from Stoffels Hornstra. FR and GJG report unrestricted institutional grants for performing research in the field of atrial fibrillation from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb/Pfizer Alliance and Daiichi Sankyo. MEWH reports grants from The Netherlands Organisation for Health Research and Development (ZonMw) and personal fees from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb/Pfizer Alliance and Daiichi Sankyo. MVH reports grants from The Netherlands Organisation for Health Research and Development (ZonMw), Dutch Healthcare Fund and Dutch Heart Foundation and grants and personal fees from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb/Pfizer Alliance, Daiichi Sankyo, Aspen and Leo Pharma. MK reports grants from The Netherlands Organisation for Health Research and Development (ZonMw), The Netherlands Thrombosis Foundation and Sobi and personal fees from Sobi and Roche. The other authors declare that they have no conflicts of interest. CONTRIBUTORS GJG, FR and AH conceived and initiated the study. LJ, SvD, MN, NW, HK, MEWH, MVH and WB provided input on the study design, with KR providing statistical and trial expertise. LJ, SvD, BK, MN, MK, LF, NW, RF, HA, FR and GJG conducted the study. LJ and SvD prepared the dataset. SvD and PvdV performed the statistical analyses. LJ SvD, BK, MEWH, MVH, FR and GJG interpreted the results. LJ, SvD, BK, MEWH, MVH, FR and GJG wrote the first version of the manuscript. All authors critically reviewed and revised the manuscript. 7
RkJQdWJsaXNoZXIy MTk4NDMw